‘Ladies and their doctors should be aware of this evidence when deciding how long to continue tamoxifen, or any additional endocrine treatment,’ said Davies in a news release. The ATLAS study results were published in The Lancet. Related StoriesSausages With Antioxidants From Berries To Prevent CancerStudy shows rare HER2 missense mutations do not spread breasts cancer on their ownMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic tumor patientsThe ATLAS trial included 6846 females with ER-positive breast cancers, half of whom got node-positive disease. Over typically 7.1 women-years of follow-up, 1328 breast malignancy recurrences were reported, including 900 situations in years 5-9 and 379 instances in years 10-14 after diagnosis. The likelihood of recurrent disease was significantly low in women assigned to get tamoxifen for a decade versus those given treatment for 5 years, with an interest rate ratio of 0.90 for a long time 5-9 and 0.75 after 10 years.The users of the executive steering committee made the decision to send the manuscript for publication and assume responsibility for the completeness and accuracy of the info and for the fidelity of the analysis to the protocol. Study Population Details of the study design previously have already been published.25 Patients 45 years or older who offered written informed consent were eligible to participate if they have been hospitalized for an acute coronary syndrome characterized by elevated cardiac biomarkers, with symptoms of acute myocardial ischemia, ischemic electrocardiographic abnormalities that were new or presumed to be new, or lack of viable myocardium on imaging. Patients without elevated cardiac biomarkers had been permitted participate if symptoms of severe myocardial ischemia had been accompanied by electrocardiographic adjustments that were brand-new or presumed to become brand-new and by additional evidence of obstructive coronary disease.25 Patients who experienced a myocardial infarction associated with percutaneous coronary intervention were also eligible.25 All patients had to be following individualized, evidence-based programs for lowering their LDL cholesterol levels by way of statin therapy and diet plan, with a target LDL cholesterol level of 100 mg per deciliter or lower and preferably 70 mg per deciliter or lower.